|
抑制素B,人类WHO参考试剂96/784
|
EA
|
96/784
|
4988
|
1-4/12周
|
|
脊髓灰质炎病毒3型[Sabin]的MAPREC分析低病毒参考值0.7%472-CWHO参考试剂96/572
|
EA
|
96/572
|
4988
|
1-4/12周
|
|
人类重组黄体生成素WHO国际标准96/602
|
EA
|
96/602
|
4988
|
1-4/12周
|
|
脊髓灰质炎病毒3型[Sabin]的MAPREC分析高病毒参考值1.1%472-CWHO参考试剂96/578
|
EA
|
96/578
|
4988
|
1-4/12周
|
|
流感病毒传染性NIB-39[H1N1]96/850
|
EA
|
96/850
|
咨询
|
1-4/12周
|
|
FMS样酪氨酸激酶3配体[人,rDNA衍生]WHO参考试剂96/532
|
EA
|
96/532
|
4988
|
1-4/12周
|
|
脑源性神经营养因子[人,rDNA衍生]WHO参考试剂96/534
|
EA
|
96/534
|
4988
|
1-4/12周
|
|
可溶性肿瘤坏死因子受体1型,[人,rDNA衍生]96/528
|
EA
|
96/528
|
4502
|
1-4/12周
|
|
胰岛素样生长因子-II[源自人类rDNA]WHO参考试剂96/538
|
EA
|
96/538
|
4988
|
1-4/12周
|
|
肝细胞生长因子/分散因子[前体],[源自人类rDNA]世界卫生组织国际标准96/556
|
EA
|
96/556
|
4988
|
1-4/12周
|
|
肝细胞生长因子/分散因子[人,rDNA衍生]WHO参考试剂96/564
|
EA
|
96/564
|
4988
|
1-4/12周
|
|
干扰素α2b[人类rDNA衍生][第3批国际标准]95/656
|
EA
|
95/656
|
4988
|
1-4/12周
|
|
抗脑膜炎球菌A群单克隆抗体95/674
|
EA
|
95/674
|
4502
|
1-4/12周
|
|
单链尿型纤溶酶原激活剂[SCuPA],[糖]95/668
|
EA
|
95/668
|
4502
|
1-4/12周
|
|
甲状旁腺激素1-84,人,重组[第1批国际标准]95/646
|
EA
|
95/646
|
4988
|
1-4/12周
|
|
抗脑膜炎球菌C群单克隆抗体95/678
|
EA
|
95/678
|
4502
|
1-4/12周
|
|
干扰素α-2a[人,rDNA衍生]世界卫生组织国际标准95/650
|
EA
|
95/650
|
4988
|
1-4/12周
|
|
单链尿型纤溶酶原激活剂[SCuPA],[非糖]95/564
|
EA
|
95/564
|
4502
|
1-4/12周
|
|
干扰素αn1[人淋巴母细胞来源]世界卫生组织国际标准95/568
|
EA
|
95/568
|
4988
|
1-4/12周
|
|
干扰素alpha-1/8[人,rDNA衍生]世界卫生组织国际标准95/572
|
EA
|
95/572
|
4988
|
1-4/12周
|
